San Francisco, 01 October 2025: The Report Next Generation Tissue Biomarkers Market (2025 - 2030) Size, Share & Trends Analysis Report By Product (Reagents & Assays, Instruments & Platforms), By Type (Genomic, Proteomic), By Technology, By Application, By End-use, By Region, And Segment Forecasts

The global next generation tissue biomarkers market size is anticipated to reach USD 5.98 billion by 2030 and is projected to grow at a CAGR of 12.74% during the forecast period, according to a new report by Grand View Research, Inc. Key driving factors such as increasing prevalence of chronic diseases, technological advancements in biomarker detection techniques, and rising demand for personalized medicines are responsible for market growth. There is a global increase in the incidence of chronic diseases such as diabetes, cancer, and other autoimmune diseases.

Increasing technological advancements for detecting next generation tissue biomarkers boost the growth of the market. The development of high throughput screening technologies such as next-generation sequencing (NGS) has significantly enhanced the ability to analyze genetic mutations and gene expression profiles in cancer tissues. Furthermore, liquid biopsies, high throughput screening technologies, epigenetic profiling, and microRNA-based biosensors are in practice for next generation tissue biomarker detection. Collectively, these technological advancements are transforming the landscape of tissue biomarker discovery, leading to more accurate diagnostics, personalized treatment strategies, and improved patient outcomes. AI and machine learning algorithms are being incorporated into digital pathology, automating the analysis of tissue images. The growing demand for personalized medicines is another key factor responsible for market growth. These personalized medicines are increasingly leveraging next-generation tissue biomarkers to tailor treatments to individual patients.

For the detection of biomarkers, in February 2025, Alida Biosciences (AlidaBio), a company in epigenomic research tools, officially announced the full commercial launch of its EpiPlex platform. This groundbreaking platform is the first to simultaneously detect and quantify multiple RNA modifications through short-read sequencing while also providing gene expression data.

In February 2025, Biofidelity, a provider of genomic solutions, unveiled details about the launch of Enspyre, an innovative target enrichment technology with a wide range of potential applications. A groundbreaking target enrichment technology that greatly improves next-generation sequencing (NGS) efficiency by selectively eliminating background DNA.

In September 2024, Genialis, an RNA biomarker company, announced the launch of Genialis krasID, the first biomarker algorithm capable of predicting patient response and clinical benefit to KRAS inhibitors (KRASi) across different tissue histologies and mutation types. Genialis krasID can assist in guiding drug development from early preclinical stages, such as compound/MOA differentiation and selection, to clinical trials.

Request sample report of Next Generation Tissue Biomarkers Market@ https://www.grandviewresearch.com/industry-analysis/next-generation-tissue-biomarkers-market-report/request/rs1

Another novel senescent cell targeting molecules was developed in October 2024. Illumina, Inc., a company in DNA sequencing and array-based technologies, introduced its MiSeq i100 Series of sequencing systems today, offering unmatched benchtop speed and ease of use to enhance next-generation sequencing (NGS) in laboratories.

In September 2021, Roche announced the release of the AVENIO Tumor Tissue CGP Kit. This new kit enhances the existing CGP portfolio from Roche and Foundation Medicine, enabling laboratories to conduct more extensive oncology research in-house. The introduction of this kit will greatly increase global access to genomic profiling by offering an in-house solution for those unable to access our tests through centralized laboratories, the company stated.

Next-generation tissue biomarkers are essential for advancing personalized medicine and play a crucial role in identifying disease conditions as in cardiovascular, chronic diseases, cancer, and several infections. Key driving factors such as the increasing prevalence of chronic diseases, technological advancements in biomarker detection techniques, and rising demand for personalized medicine are responsible for market growth.

Increasing technological advancements for detecting next generation tissue biomarkers boost the growth of the market. The development of high throughput screening technologies such as next-generation sequencing (NGS) has significantly enhanced the ability to analyze genetic mutations and gene expression profiles in cancer tissues. For instance, in November 2024, Illumina, Inc. received approval from the U.S. Food and Drug Administration (FDA) for its in vitro diagnostic (IVD) TruSight Oncology Comprehensive test, marking a significant advancement in precision oncology. This test analyzes over 500 genes in solid tumor samples to identify biomarkers that can guide targeted therapy decisions. Furthermore, liquid biopsies, high throughput screening technologies, epigenetic profiling, and microRNA-based biosensors are in practice for next generation tissue biomarker detection. Collectively, these technological advancements are transforming the landscape of tissue biomarker discovery, leading to more accurate diagnostics, personalized treatment strategies, and improved patient outcomes. AI and machine learning algorithms are being incorporated into digital pathology, automating the analysis of tissue images. This would enhance the discovery of new morphological biomarkers and improve diagnostic efficiency.

Growing demand for personalized medicines is another key factor responsible for market growth. These personalized medicines are increasingly leveraging next-generation tissue biomarkers to tailor treatments to individual patients. These biomarkers, detectable through innovative tissue analysis techniques, provide insights into tumor characteristics, guiding therapeutic decisions. In August 2024, Paige, a company in next-generation AI technology, introduced OmniScreen, an advanced AI-driven biomarker module capable of evaluating over 505 genes and detecting 1,228 molecular biomarkers. Paige's OmniScreen represents a significant advancement in personalized medicine, offering detailed insights into cancer biology and potential treatment avenues, thereby improving patient outcomes. In addition,in November 2024, Tempus AI, Inc., a company in AI-driven precision medicine, announced the clinical launch of its Immune Profile Score (IPS) algorithmic test. This multimodal biomarker serves as a prognostic indicator for adult patients with stage IV and metastatic pan-solid tumors. Thus, incorporating next-generation tissue biomarker analysis into clinical practice represents a significant stride toward personalized medicine, offering the potential for more accurate diagnoses and individualized treatment plans.